Answers are grounded in this paper and cite their sources.
Targeted post-translational modification (PTM) of a protein of interest (POI) is achieved by inducing proximity to a protein-modifying effector enzyme in cells. A number of distinct induced proximity modalities, including genetically encodable polypeptides, small heterobifunctional molecules and molecular glues, can be applied to induce proximity between virtually any two intracellular proteins. Because targeted PTM can alter protein function and fate, induced proximity offers a route to target many proteins previously considered undruggable. With several molecular glue degraders long employed in clinic and one proteolysis-targeting chimera (PROTAC) recently FDA-approved for clinical use, induced proximity modality has emerged as clinically validated and rapidly expanding avenue for drug discovery. Beyond therapeutic applications, targeted PTM provides a versatile experimental platform for dissecting the functions and consequences of specific PTMs in physiological and disease contexts. In this review, we present an up-to-date overview of advances in targeted modulation of protein PTMs using induced-proximity technologies. We also highlight several induced-proximity toolkits and include practical information on them to facilitate their rapid adoption for proof-of-concept studies on targeted modulation of PTMs in cells.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: